Member Info for Moneymunch

Biotech & Longevity: The Future of Health, Investments & Human Lifespan 🧬

Feb 24, 2025

The biotech and longevity 🏥 sectors are on an unstoppable growth trajectory, fueled by breakthrough innovations, surging investments, and an aging global population 🏃‍♂️💊. With the promise of longer, healthier lives ahead, this space has become a prime target for venture capitalists, big pharma, and tech giants alike.

📈 1. Sector Performance: A Multi-Billion-Dollar Industry on the Rise

The global biotechnology market 💰 has been expanding at an impressive rate. In 2024, it was valued at $483 billion, and it's projected to surpass $546 billion by the end of 2025 📊. This 13% compound annual growth rate (CAGR) is driven by innovations in gene therapy, precision medicine, and AI-driven drug discovery 🤖.

Source: Global Biotech Industry Outlook 2025

🔹 Longevity biotech – an industry dedicated to extending healthy lifespan ⏳ – is booming! The sector is projected to hit $600 billion by 2025 🚀, with major growth areas including:

✔️ Gene editing 🧬 (CRISPR, epigenetic reprogramming)

✔️ Regenerative medicine 🦠 (stem cells, tissue engineering)

✔️ Anti-aging therapeutics 🔄 (senolytics, cellular rejuvenation)

📌 Key Trend: The global aging population 👴📉 is a driving force behind this growth, with over 2.1 billion people expected to be 60+ by 2050. This has created massive demand for longevity-related solutions.

💰 2. Investment Growth: Big Money Meets Biotech

In 2024 alone, biotech and longevity startups raised record-breaking funding:

💵 $45 billion in venture capital flowed into the sector 🌊

🏦 Institutional investors & hedge funds doubled their stakes 📈

📑 M&A activity soared, as companies rushed to acquire cutting-edge technologies 🎯

💡 Major Deals & Investments:

Altos Labs 🏢 (funded by Jeff Bezos & Yuri Milner) secured $3 billion for cellular rejuvenation research 🦠.

Calico (Google-backed) invested in AI-powered drug discovery 🤖💊.

2025 J.P. Morgan Healthcare Conference saw $300 billion worth of deals, focusing on biotech M&As 🤝.

🚀 Why the Hype? Aging is now being treated as a disease, and investors believe they can extend human healthspan by targeting its root causes. That’s a trillion-dollar opportunity!

🏥 3. Healthcare Innovations: The Science of Longevity

🔬 Three Game-Changing Innovations:

1️⃣ AI-Driven Drug Discovery 🤖💊

AI is slashing drug development timelines ⏳ by 50-75%, making treatments faster and cheaper. Insilico Medicine and DeepMind's AlphaFold are leading the charge!

2️⃣ Gene Editing & CRISPR 🧬

Biotech startups are using CRISPR-Cas9 to reverse aging at the genetic level 🔄. Companies like Verve Therapeutics & Editas Medicine are pioneering gene therapies for longevity.

3️⃣ Senolytics & Cellular Rejuvenation 🦠

https://liquidventureexperiment.substac

Certainly looks like it Northeast, Sirt6 a panacea for multiple disease targets, aging, longevity and healthspan. Gl :-)

UTMB Study Identifies an Anti-Aging Protein as Key to Preventing Vision Loss in Glaucoma

September 20, 2024

Researchers at the University of Texas Medical Branch recently made a breakthrough in understanding how aging contributes to glaucoma, the second leading cause of irreversible blindness worldwide. Their latest study published in Molecular Therapy highlights the crucial role of the anti-aging protein, Sirt6, for preventing vision loss in millions affected by the disease.

"Our findings demonstrate that Sirt6 is essential for protecting retinal ganglion cells from aging and glaucoma-induced damage," said senior author Hua Liu, associate professor at the Department of Ophthalmology and Visual Sciences at UTMB. "When Sirt6 was removed in our animal models, we saw a significant increase in retinal cell loss, leading to vision impairment. This suggests that Sirt6 not only regulates the aging process but also plays a vital role in maintaining vision."

This research represents the first comprehensive study of anti-aging mechanism in glaucoma by experiments in multiple mouse models that collectively encompass diverse aspects of glaucomatous pathology.

"Therapeutically targeting Sirt6 offers a promising new avenue for glaucoma treatment, especially for cases that do not respond to traditional treatments aimed at reducing eye pressure," said co-senior author Wenbo Zhang, professor at the Department of Ophthalmology and Visual Sciences at UTMB. "This could be a game-changer in how we approach this disease."

https://www.utmb.edu/utmb/news-article/utmb-news/2024/09/20/utmb-study-identifies-an-anti-aging-protein-as-key-to-preventing-vision-loss-in-glaucoma

Another great interview from Eric, and very interesting he mentions Glaucoma as a target ( for the first time as far as I know ) and so maybe more detail to follow, and also looking forward to an announcement on the Dog study, "expected VERY soon on Sirt6's potential on life extension in Dogs and an angle of loss of muscle function in aging dogs"...Excitement building, Woof Woof!!!, and hopefully full market appreciation to follow. In Eric we trust!!! :-)))

News on the Dog Trial "expected very soon" according to Eric. Gla ;-)

0

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s significant progress toward securing European patents for its SIRT6 variant, marking a major milestone. The patent, which mirrors an earlier US patent, covers the composition of matter for the SIRT6 gene variant, a discovery made alongside the University of Colombia, Rochester University, and the Albert Einstein School of Medicine.

Leire explained that the SIRT6 variant was identified through research on a unique population of Jewish Ashkenazi centenarians, showing a mutation that boosts SIRT6 activity. Highlighting the gene's role in managing DNA damage and epigenomic changes, he noted, "We are in a safer position because we secure one of the very important competitive advantages over other longevity companies."

Genflow plans to apply this SIRT6 gene variant to age-related conditions such as Non-Alcoholic Steato Hepatitis (NASH), sarcopenia, and glaucoma, utilising gene therapy tools to precisely target affected areas. Beyond human applications, Leire mentioned an upcoming dog study focused on life extension and nerve cell preservation in ageing dogs, with an announcement expected soon.

As Genflow enters the national phase of patent preparation, Leire emphasised the process is largely bureaucratic with minimal risk. Stay tuned for updates as the company continues to advance its innovative longevity research.

hTtps://www.proactiveinvestors.co.uk/companies/news/1066675/genflow-biosciences-ceo-discusses-progress-towards-a-european-patent-for-sirt6-variant.html

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,833 followers

19h

🧬 Big things are happening at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

The European Patent Office has advanced #GENF's exclusive, out-licensed patent for "Variants of #SIRT6 for Use in Preventing and/or Treating Age-Related Diseases."

This marks a critical step toward securing market-specific protections across Europe - reinforcing our leadership in longevity focused #biotech.

Read the release here: hxxps://loom.ly/qA7rfT8

#GENFF #Healthspan #Longevity

............

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,833 followers

18h

🧬 What is #MASH, and why does it matter?

Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, is a progressive #LiverDisease caused by fat buildup and #inflammation. It can lead to:

🔹 Fibrosis (scarring of the liver)

🔹 #Cirrhosis (severe liver damage)

🔹 Liver failure or cancer

With no approved treatments available, MASH is a growing global health concern. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we are working to change that by harnessing the power of the SIRT6 gene, a key longevity regulator involved in DNA repair and metabolic health.

Our lead drug candidate, GF-1002, is designed to address MASH by delivering a centenarian variant of #SIRT6 to the liver. We’re pioneering new frontiers in gene therapy to tackle aging related diseases at their root.

Stay tuned as we advance - the future of liver health is evolving! 🧬

#GENF #GENFF #Healthspan

hTtps://be.linkedin.com/company/genflow-biosciences

Great news and undoubtedly strenghtens and increases the chances of a JV with Major Pharma, and the following highlights the ongoing research by Genflow's academic calloborative partners who receied $13.6m in funding towards Sirt6's R & D in January 2024. Gla ;-)

Einstein Scientists Lead Groundbreaking Search for Genetic Keys to Long, Healthy Life

Rare gene variants in centenarians discovered; $13.6 million grant will expand research.

January 16, 2024

Finding How Variants Function

The saga of a gene called SIRT6 illustrates how Dr. Vijg and his colleagues—a multicenter scientific consortium conducting four different projects—are working collaboratively to translate gene sequencing data into drugs for combating age-related diseases.

Project one of the consortium, which is involved with studying gene sequences, paid special attention to the SIRT6 gene. Vera Gorbunova, PhD, Project Leader, University of Rochester, had earlier discovered that SIRT6 codes for an enzyme associated with DNA repair, and other research indicates it protects against aging and disease. For example, SIRT6 expression is reduced in the brains of Alzheimer’s patients, and overexpressing the gene in roundworms and mice significantly extended their lifespans. Yousin Suh, PhD, Adjunct Professor, Genetics, Medicine, Albert Einstein College of Medicine, and Project Member, Columbia University, then found that a variant of SIRT6, centSIRT6, occurred twice as often among the study’s centenarians compared with control-group participants.

hTtps://montefioreeinsteinnow.org/update/2024-jan-16/einstein-human-longevity-gene-grant-renewed

RNS Number : 7707X

Genflow Biosciences PLC

20 February 2025

20 February 2025

Genflow Biosciences Plc

Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that its exclusive, out-licensed patent application for "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).

The European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.

Following the EPO's assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.

Key Details:

· Application Title: Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases

· Applicants: University of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine

· Patent Application Number: EP 22 808 414.1

· Filing Date: 13 May 2022

· Result: The application met all requirements of the European Patent Convention (EPC).

· Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025.

Genflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.

Dr. Eric Leire, CEO of Genflow commented: "This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases."

Great find Porter, and very interesting, let's hope Genflow have got a mention for good reason. Gl :-)

Focussed on Series-A investments, typical first investments will range from €3-5m, with up to €10m available per company. naturalX can act as either lead investor or co-investor, targeting consumer health startups across Europe with selected investments in North America.

Hopefully so bb123, game changing news could drop at anytime but in the meantime, an update or two and a run of positive newsflow from Eric will be very much appreciated. C'mon Eric, when you're ready!!! :-)))

Published yesterday but presumably from last week's meeting with the US Senate. Gl :-)

17th February 2025

https://www.medpagetoday.com/geriatrics/generalgeriatrics/114241

Eric Verdin, MD, president and CEO of the Buck Institute for Research on Aging in Novato, California, pointed out that due to scientific advances, "we live longer but not healthier ... Our mission is to eliminate the threat of chronic disease by addressing the aging process itself." And just as vaccines and antibiotics revolutionized medicine in the past, "aging is the next great frontier in preventive healthcare," he said. "Investing in aging research must be a priority."

Ps looks like Eric Verdin's testimony to the US senate, CEO of the Buck Institute, who sits on Genflow’s Scientific Advisory Board, got his message across. Gla :-)

BREAKING: NIH admits funding freeze is illegal, will resume issuing grants

On Monday afternoon, Popular Information broke the news that the National Institutes of Health (NIH) had frozen virtually all grant funding in violation of two federal court orders. The grants were frozen pending a review for compliance with President Trump's executive orders, including those targeting spending related to Diversity, Equity, and Inclusion (DEI). Our story was based on information from an NIH official who spoke on the condition of anonymity and internal NIH correspondence confirming the freeze.

David Super, a professor at Georgetown University Law Center and an expert on administrative law, told Popular Information that the Trump administration was "in contempt of court" and the continued funding freeze at NIH was "completely unlawful."

......

Now, staff is finally authorized to issue new and continuing grants under existing "funding policies." The grants will be issued "with “the previously approved negotiated indirect cost rates” and not0 the 15% indirect cost cap the Trump administration was seeking to impose. The cap on indirect costs would be a severe blow the biomedical research in the United States.

This means critical funding for research on everything from cancer treatments to heart disease prevention to stroke interventions will resume.

hTtps://popular.info/p/breaking-nih-admits-funding-freeze

GENE DELIVERY SYSTEMS

Proprietary innovative gene delivery systems: exo-AAV, mRNA exosomes, LNPs Centenarian variant of SIRT6 gene

GF-1002 and GF-1003

Multiple key clinical and regulatory milestones expected in next 18 months

Undervalued stock opportunity; Potential acquisition by pharmaceutical partner

HO WE ARE

Pioneering Novel Gene Therapeutics for a Longer, Healthier Life

MISSION: aging is underlying risk factor for disease, and our aim is to delivegene therapeutics that potentially halt or slow the aging process in humans and dogs

SIRT6 GENE: longevity protein that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases

PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene for treatment of MASH

SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech

ROBUST PIPELINE: advancing multiple development programs

over 24 months: MASH, Sarcopenia, Werner and life extension of dogs

SIRT6: REPAIRING DNA

SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells

SIRT6 gene codes for SIRT6 protein

Stronger SIRT6: Longer lifespan

The Ability of SIRT6 to stimulate DSB repair corelates with maximum lifespan (MLS) in rodents

5 Amino Acids determine the differential activities of SIRT6

FOCUS ON CENTENARIAN SIRT6

SIRT6 centenarian variant gene has more efficient DNA repair properties

MASH PROGRAM

Affects est. 35 million people globally

• Increasing prevalence

• Leading cause of chronic liver disease and liver transplant

Significant unmet medical need

Clear regulatory accelerated development pathway.

EMA and FDA guidelines accept:

✓ Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH

✓ Histological changes are achievable within a 12-18-month time-frame

✓ Placebo control

✓ Conditional fast-track approval

EXOSOME DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE

Genflow’s patent-pending technology has already been tested in several preclinical studies

ADVANTAGES: EXOSOME DELIVERY

Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV

2023 KEY HIGHLIGHTS & 2024 PRIORITIES

GROWING IP PORTFOLIO

Provisional patent application in 2023 for editing SIRT6 gene, linked to longevity and age-related diseases

EXPANDED MARKET

Awarded to new grants in 2023 & 2024 expanding research pipeline and size of therapeutic markets

GF-1002

Undertaking key Investigational New Drug (IND) -enabling development activities to help define pharmacological and toxicological properties and potential benefit to NASH patients

GF-1003

Commencing preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) targeting Werner Syndrome

LARGE MARKET OPPORTUNITY

NASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication

LONG LIFE IP

2 patent families SIRT6 centenarian and gene delivery (entering National Phase); Additional upcoming patent applications (entering

OLX75016 is a small interfering RNA therapy being developed for metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis and other cardiometabolic diseases. The asset works by targeting the expression of the MARC1 enzyme, which is involved in the accumulation of lipids in fat cells.

By suppressing MARC1 expression, OLX75016 could potentially reduce fat content in the liver, obesity and liver fibrosis, all known hallmarks of MASH—and other cardiometabolic conditions including obesity. In February 2024, OliX announced that it had kicked off the Phase I trial of OLX75016 in MASH.

The OliX deal moves Lilly further into the MASH space. The pharma is currently positioning its blockbuster weight-loss therapy Zepbound for expansion into MASH, with a Phase II readout in June 2024 demonstrating that more than half of patients treated with a 5-mg dose achieved absence of MASH with no worsening of fibrosis at 52 weeks. The efficacy improved with increasing doses such that nearly 75% of patients on 15 mg Zepbound achieved MASH resolution without worsening of fibrosis.

Lilly at the time said that it has “engaged with regulatory authorities” on the next steps for Zepbound in this indication, though in its full-year 2024 business review, the pharma did not list a MASH submission as one of its potential key events this year.

Elsewhere in the MASH space, Lilly’s top obesity competitor Novo Nordisk reported in November 2024 that its own blockbuster therapy Wegovy could clear MASH without worsening of fibrosis in 32.8% of patients at 72 weeks. Novo is also seeking a MASH expansion for Wegovy, with a filing expected in the first half of this year.

Also on Monday, Lilly partnered with Australian biotech AdvanCell to advance radiopharmaceutical therapies for various types of cancer.

A similar deal for Genflow more than possible. Gla :-)

OliX strikes $630 million deal with Lilly for obesity and liver disease drug

2025-02-10

OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million.

The agreement, announced last Friday, grants Lilly the rights to develop and commercialize OLX75016, an experimental RNAi-based treatment targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

OliX will continue conducting phase 1 clinical trials of OLX75016 in Australia, after which Lilly will take over subsequent development and commercialization. OliX will receive upfront and milestone-based payments tied to clinical progress. While financial specifics remain undisclosed, the company stated that all payments are non-refundable.

hTtps://www.koreabiomed.com/news/articleView.html?idxno=26559

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,829 followers

55m

Dr. Eric Verdin, Advisor to Genflow Biosciences (LON:GENF) (OTCQB:GENFF), had the privilege of addressing the Senate Special Committee on Aging last week, where he provided insights on the administration’s proposed budget cuts to the National Institutes of Health.

See the clip here:

View organization page for Buck Institute for Research on Aging, graphic

Buck Institute for Research on Aging

20,030 followers

1d Edited

Our CEO, Eric Verdin answered questions about the administration’s proposed budget cuts to The National Institutes of Health at a hearing before the Senate Special Committee on Aging this afternoon. Hear his exchange with Angela Alsobrooks D-MD here:

https://www.linkedin.com/posts/genflow-biosciences_dr-eric-verdin-advisor-to-genflow-biosciences-activity-7296194127346425856-l7MC

Let's hope so Porter, everthing firmly crossed and maybe the most perfect storm fast approaching with full market appreciation for Genflow's cutting edge science. More than possible for Major Pharma to make an early move. In the meantime, looking forward to a run of positive newsflow from Eric and the team. Excitement building!!! Gl :-)